JAC Advance Access originally published online on May 29, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 52, 71-77
© 2003 The British Society for Antimicrobial Chemotherapy
Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years
Departments of 1 Internal Medicine and 3 Laboratory Medicine, National Taiwan University Hospital No. 7, Chung-Shan South Road, Taipei; Departments of 2 Medicine and 4 Laboratory Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
Received 30 September 2002; returned 5 January 2003; revised 8 January 2003; accepted 2 April 2003
The prevalence of drug-resistant bacterial pathogens is very high in Taiwan. Accordingly, there was great concern that the introduction of fluconazole would result in rapid emergence of drug-resistant yeasts. Thus, we recommended in 1991 that fluconazole be used for treatment only. To explore the impact of this policy fluconazole susceptibility of Candida species blood culture isolates and outcome of patients with nosocomial candidaemia were monitored prospectively at National Taiwan University Hospital during 1994–2000. The MICs of fluconazole were determined by the disc diffusion method. There were 1095 episodes of nosocomial candidaemia during 1994–2000. Candida albicans was the most common species (50.4%), followed by Candida tropicalis (20.5%), Candida parapsilosis (14.2%) and Candida glabrata (12.0%). There were 0–2 isolates of Candida krusei per year. The incidence of nosocomial candidaemia and the proportion of C. glabrata peaked in 1996 and decreased thereafter. Fluconazole susceptibility was determined for 552 Candida blood isolates. Only 0.7% of blood isolates were resistant to fluconazole. Fluconazole susceptibility was 94.0% in 1994–1995 and 97.9% in 1999–2000 (P = 0.06). Attributable mortality for patients with nosocomial candidaemia was 43.2% in 1994–1995 and was 25% in 2000 (P = 0.005). Despite an increase in the incidence of nosocomial fungal infection and increased consumption of fluconazole from 1994 to 2000, there was no significant change in the susceptibility to fluconazole for bloodstream isolates of Candida species. These findings appear to be attributed to several factors. These include low prevalence of C. krusei and C. glabrata, changing patterns of use of antifungal drugs and broad-spectrum antibiotics, and efforts to improve the rational use of antifungal agents at our hospital.
Keywords: Candida, nosocomial infection, antifungal susceptibility testing, outcome
* Corresponding author. Tel: +886-2-2312-3456, ext. 5401; Fax: +886-2-2397-1412; E-mail: sc4030{at}ha.mc.ntu.edu.tw
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C.-Y. Lin, Y.-C. Chen, H.-J. Lo, K.-W. Chen, and S.-Y. Li Assessment of Candida glabrata Strain Relatedness by Pulsed-Field Gel Electrophoresis and Multilocus Sequence Typing J. Clin. Microbiol., August 1, 2007; 45(8): 2452 - 2459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, G. W. Procop, and M. G. Rinaldi Multicenter Comparison of the VITEK 2 Yeast Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Fluconazole against Candida spp. J. Clin. Microbiol., March 1, 2007; 45(3): 796 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Pfaller and D. J. Diekema Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem Clin. Microbiol. Rev., January 1, 2007; 20(1): 133 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Girmenia, G. Pizzarelli, F. Cristini, F. Barchiesi, E. Spreghini, G. Scalise, and P. Martino Candida guilliermondii Fungemia in Patients with Hematologic Malignancies. J. Clin. Microbiol., July 1, 2006; 44(7): 2458 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-W. Chen, Y.-C. Chen, H.-J. Lo, F. C. Odds, T.-H. Wang, C.-Y. Lin, and S.-Y. Li Multilocus Sequence Typing for Analyses of Clonality of Candida albicans Strains in Taiwan. J. Clin. Microbiol., June 1, 2006; 44(6): 2172 - 2178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Chen, R. N. Kumar, Y.-H. Feng, C.-H. Ho, J.-Y. You, C.-C. Liao, C.-H. Tseng, P. Mavros, W. C. Gerth, and Y.-C. Chen Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan J. Antimicrob. Chemother., June 1, 2006; 57(6): 1181 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Golan, M. P. Wolf, S. G. Pauker, J. B. Wong, and S. Hadley Empirical Anti-Candida Therapy among Selected Patients in the Intensive Care Unit: A Cost-Effectiveness Analysis Ann Intern Med, December 20, 2005; 143(12): 857 - 869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-W. Chen, H.-J. Lo, Y.-H. Lin, and S.-Y. Li Comparison of four molecular typing methods to assess genetic relatedness of Candida albicans clinical isolates in Taiwan J. Med. Microbiol., March 1, 2005; 54(3): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.-R. Hsueh, Y.-J. Lau, Y.-C. Chuang, J.-H. Wan, W.-K. Huang, J.-M. Shyr, J.-J. Yan, K.-W. Yu, J.-J. Wu, W.-C. Ko, et al. Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003 Antimicrob. Agents Chemother., February 1, 2005; 49(2): 512 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, A. Espinel-Ingroff, and R. N. Jones Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Plate for Antifungal Susceptibility Testing of the New Triazoles Voriconazole, Posaconazole, and Ravuconazole J. Clin. Microbiol., October 1, 2004; 42(10): 4577 - 4580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Pfaller, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 J. Clin. Microbiol., July 1, 2004; 42(7): 3142 - 3146. [Abstract] [Full Text] [PDF]
|
|